Severe Cornea Damage

BRM423 is targeted to treat severe corneal damage.

BRM423 is novel synthetic peptide derived from human Pigment Epithelium-Derived Factor (PEDF). Its active ingredient is the same as the BRM421 for Dry Eye Syndrome, but it is targeted to treat severe corneal damage.

Based on BRIM’s proprietary PDSP technology platform, BRIM intends to rapidly advance development of this novel treatment for corneal damage repair.

About Corneal Damage

When the cornea is damaged, corneal renewal and repair are supported by limbal stem cells (LSCs) that reside in the limbus. In cases where LSCs are insufficient or dysfunctional, corneal damage cannot be healed and may cause blindness. Losing LSCs due to diseases or accidents is a common cause of blindness.

Demonstrated superior and fast corneal healing

BRM423 has proven superior and fast corneal healing efficacy in pre-clinical studies. This novel neurotrophic peptide stimulates corneal wound healing and corneal repair. BRM423’s PEDF-derived short peptide (PDSP) was previously shown to promote LSC growth, expansion and regeneration. Furthermore, PDSP-expanded LSCs maintain their ability to differentiate into corneal cells as well as the ability of self-renewal. Most importantly, PDSP significantly accelerated corneal wound healing in animal models, and demonstrated the corneal re-epithelialization function of PEDF, which may also promote LSC expansion. BRM423’s safety and early on-set efficacy were shown in two clinical studies of BRM421 and can leverage these data to enter Clinical Phase II.

Download BRIM's Corporate Overview

This site is registered on as a development site.